| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | 0.043 | 0.2 |
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | 0.047 | 0.2 |
| mRNA | WAY-362450 | CTRPv2 | pan-cancer | AAC | 0.048 | 0.2 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.059 | 0.2 |
| mRNA | 17-AAG | GDSC1000 | pan-cancer | AAC | 0.042 | 0.2 |
| mRNA | BRD-K75293299 | CTRPv2 | pan-cancer | AAC | 0.091 | 0.2 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.045 | 0.2 |
| mRNA | JQ-1:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.043 | 0.2 |
| mRNA | PIK-93 | CTRPv2 | pan-cancer | AAC | -0.044 | 0.2 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | -0.059 | 0.2 |